Reuben Harris, PhD of University of Minnesota, Minneapolis, MN discusses future directions for APOBEC studies. Dr Harris’ laboratory is interested in understanding the APOBEC mechanism in order to reveal some clinical vulnerabilities. In addition, Dr Harris collaborates with others to target evolvability and shut off APOBEC-3B or APOBEC-3H to ultimately slow down tumor mutation rate and improve clinical outcomes. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates